Minghui Pharmaceutical
Suite 6305, Building 6, 338 Jialilue Road, Pilot Free Trade Zone, Pudong New Area, Shanghai, Not provided, China
Overview
Minghui Pharmaceutical is a late-stage clinical biopharmaceutical company led by CEO Dr. Guoqing Cao, focused on developing new medicines for oncology and immunology. The company leverages proprietary technology platforms to build a differentiated pipeline of novel therapies. Its clinical priorities include a PD-1/VEGF bispecific antibody and combination strategies with antibody-drug conjugates (ADCs). Minghui also plans a commercial launch of a topical JAK inhibitor in China. The company intends to use new financing to advance its clinical programs and support the planned product launch. Headquarters are in Singapore.
- Total raised
- $131M
- Funding rounds
- 1
- Latest round
- Equity
- Latest activity
- Aug 2025
Industries
- Biopharma
- Biotechnology
- Medical
- Pharmaceutical
- Product Research
- Therapeutics
Recent funding
Equity
Aug 2025
$131M
Team
No current team members are available.